Add-on therapy in epilepsy with calcium entry blockers. 1986

J Overweg, and D Ashton, and F de Beukelaar, and C D Binnie, and A Wauquier, and A van Wieringen

In view of the known role of Ca2+ in the paroxysmal depolarization shifts of epileptic neurones, the possibility arises that certain Ca2+ entry blockers possess antiepileptic activity. The only drug of the class which readily passes the blood-brain barrier is flunarizine. This is effective in experimental models of epilepsy and produced significant seizure reduction in two therapeutic trials in therapy-resistant patients. It has few and mild side effects at therapeutic blood levels.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D004827 Epilepsy A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313) Aura,Awakening Epilepsy,Seizure Disorder,Epilepsy, Cryptogenic,Auras,Cryptogenic Epilepsies,Cryptogenic Epilepsy,Epilepsies,Epilepsies, Cryptogenic,Epilepsy, Awakening,Seizure Disorders
D005260 Female Females
D005444 Flunarizine Flunarizine is a selective calcium entry blocker with calmodulin binding properties and histamine H1 blocking activity. It is effective in the prophylaxis of migraine, occlusive peripheral vascular disease, vertigo of central and peripheral origin, and as an adjuvant in the therapy of epilepsy. Flunarizin,Flunarizine Dihydrochloride,Flunarizine Hydrochloride,R-14950,Sibelium,Dihydrochloride, Flunarizine,Hydrochloride, Flunarizine,R 14950,R14950
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

J Overweg, and D Ashton, and F de Beukelaar, and C D Binnie, and A Wauquier, and A van Wieringen
January 1986, Functional neurology,
J Overweg, and D Ashton, and F de Beukelaar, and C D Binnie, and A Wauquier, and A van Wieringen
August 1981, Hospital practice (Office ed.),
J Overweg, and D Ashton, and F de Beukelaar, and C D Binnie, and A Wauquier, and A van Wieringen
January 1986, European neurology,
J Overweg, and D Ashton, and F de Beukelaar, and C D Binnie, and A Wauquier, and A van Wieringen
January 2001, The Cochrane database of systematic reviews,
J Overweg, and D Ashton, and F de Beukelaar, and C D Binnie, and A Wauquier, and A van Wieringen
March 2013, The Cochrane database of systematic reviews,
J Overweg, and D Ashton, and F de Beukelaar, and C D Binnie, and A Wauquier, and A van Wieringen
June 1989, Cardiovascular drugs and therapy,
J Overweg, and D Ashton, and F de Beukelaar, and C D Binnie, and A Wauquier, and A van Wieringen
April 1992, Cardiovascular drugs and therapy,
J Overweg, and D Ashton, and F de Beukelaar, and C D Binnie, and A Wauquier, and A van Wieringen
October 1988, JPMA. The Journal of the Pakistan Medical Association,
J Overweg, and D Ashton, and F de Beukelaar, and C D Binnie, and A Wauquier, and A van Wieringen
June 1987, Circulation,
J Overweg, and D Ashton, and F de Beukelaar, and C D Binnie, and A Wauquier, and A van Wieringen
February 1983, Federation proceedings,
Copied contents to your clipboard!